Rocket Lab's Balance Sheet Is the Real Launchpad Now

Rocket Lab heads into Monday's quarterly report with its stock still smarting from an 11% single-day drop — a slide that, by media accounts, had no company-specific trigger behind it. The selling swept through growth names as Qualcomm's weak numbers and worries about tighter AI infrastructure spending after the US elections dented appetite for expensive future promises. Rocket Lab sells no AI compute, yet it was pulled into the same undertow as investors trimmed speculative positions well beyond the immediate AI trade.

That sets an unusually pointed test for Monday's release, due after the market close. The question is no longer whether demand exists — the order book answers that — but whether the company can convert a bulging backlog into a business that eventually pays for itself.

Demand Is Not the Problem

The top line makes the case. Revenue climbed 62% to $234.07 million in the second quarter of 2026, and the backlog stood at $2.36 billion. Management is guiding third-quarter sales of $250–265 million, with an adjusted EBITDA loss of $17–23 million.

Growth, in other words, still comes with red ink. The forecast also points to an adjusted gross margin of 35–37%, down from 41.5% in the prior quarter — a detail that deserves as much scrutiny as the revenue line. Sales are meant to rise while profitability at that level slips, so investors will want to see how demand, margin and cost control fit together.

Cash is the other half of the story. Free cash outflow reached $110.1 million in the second quarter of 2026, up from $77.4 million in the first. That trajectory raises the bar for every new commitment: large outlays are defensible when they buy verifiable progress on products, deliveries and future earning power. The longer key projects slip, the more closely the use of capital will be watched.

Neutron Slips, and Time Becomes a Cost

The debut of Neutron has been pushed to 2027 after voids were found in the carbon composite layers of a forward tank dome. Rocket Lab has reworked the manufacturing process and is building a replacement dome. Inspection, first-stage assembly and pressure and cryogenic testing are slated for completion in the first quarter of 2027, with a more precise launch date to follow only after that.

Neutron matters because it is designed to carry larger payloads than Electron for commercial and government customers, and because it underpins Rocket Lab's effort to compete with SpaceX in the launch market. A delay can be justified economically if it retires technical risk and keeps the extra funding need manageable. For the shares, that shifts the weight onto precise disclosures about the test program and schedule.

Analysts are already looking well past Monday. Cantor Fitzgerald keeps an Overweight rating and a $122 price target; Citizens reaffirms Market Outperform but trims its target to $90 from $130. Citizens expects the first Neutron launch by the end of the second quarter of 2027 — a reminder of how far out the relevant horizon now stretches.

The Bill Lands on Shareholders

The capital question sharpens further with the pending acquisition of Iridium for roughly $8 billion. In September, Rocket Lab issued 29.3 million shares through an equity sales program. Fresh equity widens the room to maneuver, but it also spreads future earnings across more stock. That trade pays off for existing holders only if the acquired business and the projects it funds generate enough additional value — which puts earnings per share on par with headline growth as a yardstick.

Rocket Lab has genuine demand in hand and ambitious technical and strategic plans on the table. Monday's report will be read for three things: a credible account of cash needs, tangible progress on Neutron, and a clear link between expansion and future profit per share. That is where a financed future either becomes an economically convincing one — or doesn't.